Literature DB >> 11519046

Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading.

K M Lally1, S Mocellin, G A Ohnmacht, M B Nielsen, M Bettinotti, M C Panelli, V Monsurro, F M Marincola.   

Abstract

The basis of intra-tumoral and systemic T cell reactivity toward cancer remains unclear. In particular the role that peripheral stimuli, whether endogenous or exogenous, play in shaping acquired immune response toward cancer remains poorly understood. In this study we document the surfacing of systemic immune reactivity toward a cryptic epitope from the MAGE-12 gene (MAGE-12:170-178), after temporary regression of a single melanoma metastasis, in response to gp100/PMel17-specific vaccination. This emergence was unlikely related to unusually high expression of MAGE-12 by the tumor, by the influence of analog epitopes to MAGE-12:170-178. Because MAGE-12 was unlikely to be expressed at sites other than the tumor, the demonstration of MAGE-12:170-178 reactivity in post- but not pre-vaccination circulating lymphocytes suggests that the systemically observed immune response was influenced by events induced by the vaccine at tumor site or draining lymph nodal areas. Possibly, as suggested by pre-clinical models, immunologic ignorance is the default response toward cancer in humans unless unusual stimulatory conditions occur in peripheral tissues. Surfacing of MAGE-12 specificity occurred in association with loss of gp100/PMel 17 targeted by the vaccine. This finding suggests that vaccinations might have effects beyond their intrinsic specificity and may trigger broader immune responses through epitope spreading by inducing changes within the tumor microenvironment. This may have important practical implication for the development of immunization strategies. Published 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11519046     DOI: 10.1002/ijc.1420

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.

Authors:  Douglas G McNeel; Jordan T Becker; Jens C Eickhoff; Laura E Johnson; Eric Bradley; Isabel Pohlkamp; Mary Jane Staab; Glenn Liu; George Wilding; Brian M Olson
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

Review 2.  Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines.

Authors:  Mayumi Nakagawa; William Greenfield; Andrea Moerman-Herzog; Hannah N Coleman
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

3.  NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.

Authors:  Paul Spear; Amorette Barber; Agnieszka Rynda-Apple; Charles L Sentman
Journal:  Immunol Cell Biol       Date:  2013-04-30       Impact factor: 5.126

Review 4.  Strategies to overcome obstacles to successful immunotherapy of melanoma.

Authors:  F Pandolfi; R Cianci; S Lolli; I S Dunn; E E Newton; T J Haggerty; L A Boyle; J T Kurnick
Journal:  Int J Immunopathol Pharmacol       Date:  2008 Jul-Sep       Impact factor: 3.219

5.  Vaccination with tumor cells pulsed with foreign peptide induces immunity to the tumor itself.

Authors:  Tobias R Schlingmann; Frauke H Rininsland; Wolf C Bartholomae; Haydar Kuekrek; Paul V Lehmann; Magdalena Tary-Lehmann
Journal:  Clin Immunol       Date:  2009-07-09       Impact factor: 3.969

Review 6.  Tumor vaccines and beyond.

Authors:  Jan Joseph Melenhorst; Austin John Barrett
Journal:  Cytotherapy       Date:  2010-11-10       Impact factor: 5.414

7.  Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines.

Authors:  Roopa Srinivasan; Jedd D Wolchok
Journal:  J Transl Med       Date:  2004-04-16       Impact factor: 5.531

8.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

Review 9.  Identification of human tumor antigens recognized by T-cells and their use for immunotherapy.

Authors:  Yutaka Kawakami
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.319

10.  A modified human ELISPOT assay to detect specific responses to primary tumor cell targets.

Authors:  Anatoli Malyguine; Susan L Strobl; Kimberly A Shafer-Weaver; Tracy Ulderich; Angela Troke; Michael Baseler; Larry W Kwak; Sattva S Neelapu
Journal:  J Transl Med       Date:  2004-03-29       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.